Indaptus Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -1,822 | -2,541 | -8,112 | -2,975 |
Net Income | -1,794 | -2,541 | -8,112 | -2,975 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -1,927 | -7,009 | -3,190 | -3,054 |
Cash | 7,553 | 1,497 | 8,507 | 5,825 |
Basic Shares | 116,131 | 10,956 | 2,167 | 997 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | -1 | ||
EBITDA | -20,848 | -15,021 | -15,422 | -14,321 |
EBIT | -15,022 | -15,423 | -14,322 | |
Net Income | -20,848 | -15,022 | -15,423 | -14,322 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -14,823 | -12,323 | -13,405 | -13,250 |
Cash | 8,507 | 5,786 | 13,362 | 9,626 |
Basic Shares | 966 | 334 | 300 | 295 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.02 |
2025-12-31 | -$9.19 |
2025-09-30 | -$2.98 |
2025-06-30 | -$9.09 |